World’s 1st Nanomedicine CDMO
& Clinical-Phase Fill-Finish CMO

We develop and scale nanoparticle drug substance, and fill clinical-phase batches in a purpose-built sterile suite aligned with the current EU GMP Annex 1 — one partner, one hand-off avoided.

About

OmniParticles

We specialize in nanoparticle medicines on the drug substance side, and provide aseptic fill-finish across modalities for clinical supply.

Two Services, One Quality System

Nanoparticle
Drug Substance

CDMO

+

Aseptic Sterile Drug Product

CMO

Drug Substance CDMO

Autosampler loaded with sample vials for biopharmaceutical analysis at Omniparticles CDMO laboratory

More

End-to-end CDMO for nanoparticle drug substances, from concept translation and formulation refinement to scale-up and GMP mass production with CMC support.

CDMO Case Highlights

Stainless steel pharmaceutical processing vessel with pressure gauge and valves in a GMP-compliant CDMO facility

More

has developed world’s first FDA IND approved anti-inflammatory cerium oxide nanomedicine for acute AND chronic diseases (from critical to degenerative conditions).

OmniParticles

Aseptic Fill-Finish

More

Aseptic fill-finish for preclinical and Phase I/II/III clinical supply. We fill batches of 2,000–5,000 vials under Grade A conditions in open RABS, with a fully single-use product-contact train.

GMP-compliant Facility

State-of-the-art biopharmaceutical laboratory with GMP-compliant equipment and large-scale research facilities

More

Our drug substance CDMO is optimized for early-stage nanomedicine development, and our GMP-compliant facility enables in-house drug substance manufacturing and aseptic fill-finish.

One Partner from Drug Substance to Drug Product

Nanoparticle drug substance development and GMP manufacturing, with aseptic fill-finish for clinical-phase supply

Contact us

About

OmniParticles

We specialize in nanoparticle medicines on the drug substance side, and provide aseptic fill-finish across modalities for clinical supply.

Two Services, One Quality System

Drug Substance CDMO

End-to-end CDMO for nanoparticle drug substances, from concept translation and formulation refinement to scale-up and GMP mass production with CMC support.

CDMO Case Highlights​

has developed world’s first FDA IND approved anti-inflammatory cerium oxide nanomedicine for acute AND chronic diseases (from critical to degenerative conditions).

OmniParticles

Aseptic Fill-Finish

Aseptic fill-finish for preclinical and Phase I/II/III clinical supply. We fill batches of 2,000–5,000 vials under Grade A conditions in open RABS, with a fully single-use product-contact train.

GMP-compliant Facility

Our drug substance CDMO is optimized for early-stage nanomedicine development, and our GMP-compliant facility enables in-house drug substance manufacturing and aseptic fill-finish.

CDMO Case Highlights